Program characteristics | Program outcomes | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
First author, year of publication | Calendar year of data collection | Population | Country and HCV prevalence according to CDC[23] | Setting of screening | Duration of screening program | Other tests | Prescreening selection | Media activities | Screening uptake and anti-HCV prevalence (95% CI) | Risk profile of identified HCV cases/Risk factors associated with HCV | Follow-up of HCV-infected individuals |
Alexanian et al. 2009 [84] | NR | Pregnant women | UK (1.1%): London | Antenatal clinic | 8Â years, Hospital records search | HBV, HIV | No | NR | Scr. uptake: NR | NR | In total, 73.0% (84/115) of patients had chronic HCV, of whom 55.9% (47/84) were lost to follow-up, 10.7% (9/84) deferred treatment, 4.8% (4/84) were on treatment, and 17.9% (15/84) completed treatment. Of these 15, 12 achieved SRV, 1 relapsed, and two failed to respond. |
Prevalence: 0.4 (115/31081; 95% CI: 0.3-0.4)* | |||||||||||
Outcomes: RNA rate: 73.0% (84/115) Start treatment: 67.9% (19/28) SVR: 80.0% (12/15) | |||||||||||
Abusheikha et al. 1999 [85] | 1996-1998 | Couples receiving fertility treatment | UK (1.1%): Cambridge | Bourn Hall clinic, infertility hospital | 3Â years | HIV, HBV | No | NR | Scr. uptake: NR Prevalence: 0.5% (9/1658; 95% CI: 0.3-1.0)** | NR | All patients were counseled by senior medical staff. Outcomes: RNA rate: NR Start treatment: NR SVR: NR |
Leikin et al. 1994 [86] | 1991-1992 | Pregnant women who are at risk for perinatal complications | USA (1.9%): Valhalla | Hospital (obstetric) | 19,5 months | ALT | No | NR | Scr. uptake: NR Prevalence: 4.6% (78/1700; 95% CI: 3.7-5.7)* | Multivariable regr. analysis: - History of IDU - Other drug use - Age > 30 - Incarceration - Blood transfusion | In total, 96.2% (75/78) of the patients returned for follow-up. No further details reported. Outcomes: RNA rate: NR Start treatment: NR SVR: NR |
Ward et al. 2000 [87] | 1997-1999 | Pregnant women | UK (1.1%): London | Antenatal clinic | 18Â months | HBV | No | Yes | Scr. uptake: 98.0% (4727/4825) Prevalence: 0.8% (38/4729; 95% CI: 0.6-1.1)*** | Univariate regr. analysis: - History of IDU - HCV-infected partner - Tattoo - Partner IDU | In total, 71.1% (27/38) had chronic HCV, and 85.2% (23/27) were offered follow-up appointments so far. Of those, 82.6% (19/23) attended for further investigations. Outcomes: RNA rate: 71.1% (27/38) Start treatment: NR SVR: NR |
Costa et al. 2009 [88] | 2004-2005 | Pregnant women | Brazil (1%): Central Brazil, Goiania | Antenatal clinics | NR | HIV and seven other infectious diseases (not specified) | No | NR | Scr. uptake: 99.9% (28561/28576) Prevalence: 0.2% CHCV (43/28561; 95% CI: 0.1-0.2%)**** | Multivariable regr. analysis: - Older age - >3 pregnancies(no data on risk factors collected) | Patients were referred for free of cost medical counseling (no results reported). Outcomes: RNA rate: n/a Start treatment: NR SVR: NR |